---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-137688"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:02:37.769736+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akebia shareholders reject 1-for-5 to 1-for-20 reverse stock split at special meeting

## Summary
- Reverse stock split (Proposal 1a) not approved: 77,934,578 for, 57,085,942 against, 563,365 abstain.
- Proportional authorized share reduction (Proposal 1b) also not approved: 78,473,738 for, 54,949,341 against.
- Adjournment proposal approved: 77,956,153 for, 56,291,429 against, 0 broker non-votes.
- Proposal 2 (authorized shares adjustment) withdrawn after Proposal 1b failed.

## SEC filing metadata
- accession: 0001193125-23-137688
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000119312523137688/0001193125-23-137688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000119312523137688/d417546d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-137688
- JSON: https://secwatch.observer/filing/0001193125-23-137688.json
- Plain text: https://secwatch.observer/filing/0001193125-23-137688.txt

## Key facts
- Shareholder Votes
  Akebia Therapeutics, Inc. shareholders rejected Approval of an amendment to the Ninth Amended and Restated Certificate of Incorporation to decrease the number of authorized shares of Common Stock on a basis proportional to the reverse stock split ratio. at the 2023-05-04 meeting.
  - Proposal: charter amendment
  - Outcome: failed
  - Meeting: 2023-05-04
  source text: The proposal to, in connection with Proposal 1(a), decrease the number of authorized shares of the Company’s Common Stock on a basis proportional to the reverse stock split ratio (“Proposal 1(b)” and, together with Proposal 1(a), the “Reverse Stock Split Proposals”) was not approved as follows: Votes For: 78,473,738 Votes Against: 54,949,341 Abstentions: 647,283
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312523137688/0001193125-23-137688-index.htm
- Shareholder Votes
  Akebia Therapeutics, Inc. shareholders rejected Approval of an amendment to the Ninth Amended and Restated Certificate of Incorporation to effect a reverse stock split of Common Stock at a ratio of not less than 1-for-5 and not greater than 1-for-20, with the exact ratio to be set at the discretion of the Board of Directors. at the 2023-05-04 meeting.
  - Proposal: reverse split
  - Outcome: failed
  - Meeting: 2023-05-04
  source text: The proposal to approve an amendment to the Company’s Ninth Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s outstanding common stock, $0.00001 par value per share (the “Common Stock”), at a ratio of not less than 1-for-5 and not greater than 1-for-20, with the exact ratio to be set within that range at the discretion of the Company’s Board of Directors, at any time prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Special Meeting (“Proposal 1(a)”), was not approved as follows: Votes For: 77,934,578 Votes Against: 57,085,942 Abstentions: 563,365
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312523137688/0001193125-23-137688-index.htm
- Shareholder Votes
  Akebia Therapeutics, Inc. shareholders approved Approval of an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of either of the Reverse Stock Split Proposals at the 2023-05-04 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-05-04
  source text: The proposal to approve an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of either of the Reverse Stock Split Proposals (Proposal 1(a) or 1(b)) was approved as follows: Votes For: 77,956,153 Votes Against: 56,291,429 Abstentions: 1,336,302 Broker Non-Votes 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312523137688/0001193125-23-137688-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.